- BCDA Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
BioCardia (BCDA) CORRESPCorrespondence with SEC
Filed: 1 Dec 23, 12:00am
BioCardia, Inc.
320 Soquel Way
Sunnyvale, California 94085
December 1, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Cindy Polynice
Re: | BioCardia, Inc. |
Registration Statement on Form S-3 |
File No. 333-275099 |
Acceleration Request |
Requested Date: December 5, 2023
Requested Time: 4:30 p.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, BioCardia, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-275099) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with the Company’s counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Austin March at (512) 338-5410.
[Signature page follows]
| Sincerely, |
| |
BioCardia, Inc. | |||
|
|
|
|
| /s/ Peter Altman |
| |
Peter Altman | |||
President and Chief Executive Officer and Director |
cc: | David McClung, BioCardia, Inc. |
Michael J. Danaher, Wilson Sonsini Goodrich & Rosati, P.C. |
Austin D. March, Wilson Sonsini Goodrich & Rosati, P.C. |